Metabolomic Technologies Inc. (MTI) uses a new and emerging science known as metabolomics to detect differences in urine samples from people who have cancer adenomas (precancerous polyps) and normal people.

MTI's lead products are diagnostic screening tests that will improve overall colorectal cancer detections (ColoDx™), and earlier detection of colonic adenomatous (precancerous polyps) polyps (PolypDx™). If caught early at the adenomatous polyp stage, colorectal cancer is very treatable, and this makes the prospect of early diagnosis of cancer, or even diagnosis at a precancerous stage, very exciting.

MTI's clinical trial in 1200 patients (soon to be 2000) has direct comparison of urine metabolomics with 1 fecal guaiac test (FGT), 2 fecal immunochemical tests (FIT), and the reference test, colonoscopy. This study demonstrates an enormous superiority of sensitivity of urine metabolomics using PolypDx™ and ColoDx™, over FGT and FIT in detecting colonic adenomatous polyps and colorectal cancer, respectively.

MTI's diagnostics thus provide the potential for game-changing enhancements in the screening of patients for colorectal cancer and colonic polyps. There is absolutely no competition to MTI's PolypDx™ and ColoDx™ products for a simple, non-invasive, single spot urine colon cancer screening test.